Page last updated: 2024-08-18

pyrroles and Lymphoma, Non-Hodgkin

pyrroles has been researched along with Lymphoma, Non-Hodgkin in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Brana, I; Brown, RJ; Doger, B; Galvao, V; Genta, S; Gu, J; Hansen, AR; Hernández, T; Kalota, A; Lauring, J; Lenox, L; Mehta, J; Mistry, P; Moreno, V; Pastore, F; Patel, B; Patel, MR; Preis, M; Spreafico, A; Vieito, M; Wang, JS	1
Blay, JY; Coscas, Y; Khayat, D; Pivot, X; Soria, JC; Spano, JP	1
Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A	1
Engel, JB; Halmos, G; Hammann, B; Keller, G; Nagy, A; Schally, AV	1

Reviews

1 review(s) available for pyrroles and Lymphoma, Non-Hodgkin

Article	Year
Added value of molecular targeted agents in oncology. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Indoles; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, ErbB-2; Rituximab; Sunitinib; Trastuzumab	2011

Article

Year

Added value of molecular targeted agents in oncology.

Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8

Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Indoles; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, ErbB-2; Rituximab; Sunitinib; Trastuzumab

2011

Trials

1 trial(s) available for pyrroles and Lymphoma, Non-Hodgkin

Article	Year
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 09-15, Volume: 29, Issue:18 Topics: Adult; Carcinoma, Adenoid Cystic; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Protein-Arginine N-Methyltransferases; Pyrimidines; Pyrroles	2023

Other Studies

2 other study(ies) available for pyrroles and Lymphoma, Non-Hodgkin

Article	Year
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Experimental hematology, 2011, Volume: 39, Issue:10 Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein	2011
Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. International journal of cancer, 2005, May-01, Volume: 114, Issue:5 Topics: Animals; Antineoplastic Agents; Body Weight; Doxorubicin; Humans; Kinetics; Leukocytes; Lymphoma, Non-Hodgkin; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Peptides; Pyrroles; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin; Time Factors	2005

Article

Year

The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.

Experimental hematology, 2011, Volume: 39, Issue:10

Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein

2011

Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.

International journal of cancer, 2005, May-01, Volume: 114, Issue:5

Topics: Animals; Antineoplastic Agents; Body Weight; Doxorubicin; Humans; Kinetics; Leukocytes; Lymphoma, Non-Hodgkin; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Peptides; Pyrroles; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin; Time Factors

2005